You just read:

Mirati Therapeutics Announces Initial Data In Renal Cell Carcinoma From Ongoing Investigator Sponsored Clinical Trial Of Sitravatinib In Combination With Nivolumab At The 2020 ASCO Genitourinary Cancers Symposium

News provided by

Mirati Therapeutics, Inc.

Feb 15, 2020, 11:30 ET